APARICIO HERNANDEZ, R.; PUERRO VICENTE, M.; CABANES MARISCAL, MªA.    PRATS OLIVAN, P.. Possitive assessment of drugs: March, April and May 2017. []. , 73, 3, pp.162-172. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712017000300005.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

: Beclometasona Dipropionato / Formoterol / Glicopirronio Bromuro; Trimbow^®; Brodalumab; Kyntheum^®; Cariprazina; Reagila^®; Cenegermin; Oxervate^®; Cerliponasa Alfa; Brineura^®; Condrocitos Humanos Autólogos Asociados a Matriz; Spherox^®; Dinutuximab Beta; Dinutuximab Beta Apeiron^®; Etanercept; Erelzi^®; Fluciclovina; ¹⁸f Axumin^®; Fumarato Dimetilo; Skilarence^®; Inotuzumab Ozogamicina; Besponsa^®; Nonacog Beta Pegol; Refixia^®; Nusinersen; Spinraza^®; Patirómero; Veltassa^®; Pentosano Polisulfato de Sodio; Elmiron^®; Rituximab; Rixathon^®; Riximyo^®; Sarilumab; Kevzara^®; Trientina Tetraclorhidrato; Cuprior^®; Vacuna Meningocócica del Grupo B; Adnr; Adsorbida; Trumenba^®.

        · |     · |     · ( pdf )